Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: TCR-T cell therapies targeting shared driver cancer mutations - Anocca

Next Previous
Drug Profile

Research programme: TCR-T cell therapies targeting shared driver cancer mutations - Anocca

Alternative Names: BRAF-V600E targeting TCR-T cell therapies - Anocca; KRAS-G12D targeting TCR-T cell therapies - Anocca; KRAS-G12V targeting TCR-T cell therapies - Anocca; P53-R175H targeting TCR-T cell therapies - Anocca; RAC1-P29S targeting TCR-T cell therapies - Anocca; Research programme: cancer driving genetic mtations targeting TCR-T cell therapies - Anocca

Latest Information Update: 28 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anocca
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Dec 2025 No recent reports of development identified for preclinical development in Cancer in Sweden (Parenteral)
  • 31 May 2023 Anocca plans phase I/IIa clinical trials for Cancer in 2024
  • 16 Nov 2021 Research programme: TCR-T cell therapies targeting cancer driving genetic mtations targeting - Anocca is available for licensing as of 16 Nov 2021. https://www.anocca.com/partnering/

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top